Cancer.Net Associate Editor: Lymphoma
University of Virginia Health System, Charlottesville, VA
Dr. Michael E. Williams is the Byrd S. Leavell Professor of Medicine and Professor of Pathology at the University of Virginia (UVA) School of Medicine. He also serves as the Chief of the Hematology/Oncology Division and Director of the Hematologic Malignancies Program at the UVA Cancer Center.
Dr. Williams received his medical degree from the University of Cincinnati College of Medicine and a Master of Science from the Harvard School of Public Health. He completed his medicine residency, chief residency, and fellowship in hematology/oncology at the UVA Health System in Charlottesville.
Dr. Williams’ clinical and research interests are in novel treatment approaches for non-Hodgkin lymphomas, mantle cell lymphoma, and CLL, including targeted therapeutics and immunotherapy. He serves on the scientific advisory boards of the Lymphoma Research Foundation and the European Mantle Cell Lymphoma Network, and is vice-chair of the Eastern Cooperative Oncology Group Lymphoma Core Committee. He also serves as chair of the Hematology Subspecialty Board of the American Board of Internal Medicine (ABIM), and he is an ABIM Council Member.
He participates regularly in national and international programs devoted to education and research in lymphoma and hematologic malignancies.
Disclosures: In the past two years, Dr. Williams has served as a consultant and/or advisor for Celgene, Gilead, Takeda, and TG Therapeutics, and his institution has received research funding from Abbvie, Celgene, Genentech, Janssen, Pharmacyclics and Takeda.
Last updated: November 2015